14.62
-0.3688(-2.46%)
Currency In USD
| Previous Close | 14.99 |
| Open | 14.54 |
| Day High | 15.28 |
| Day Low | 14.53 |
| 52-Week High | 26.99 |
| 52-Week Low | 12.12 |
| Volume | 1,214 |
| Average Volume | 8,737 |
| Market Cap | 38.25M |
| PE | -5.22 |
| EPS | -2.8 |
| Moving Average 50 Days | 18.51 |
| Moving Average 200 Days | 16.4 |
| Change | -0.37 |
If you invested $1000 in vTv Therapeutics Inc. (VTVT) 10 years ago, it would be worth $33.55 as of July 01, 2025 at a share price of $14.616. Whereas If you bought $1000 worth of vTv Therapeutics Inc. (VTVT) shares 5 years ago, it would be worth $159.57 as of July 01, 2025 at a share price of $14.616.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
vTv Therapeutics to Participate in the H.C. Wainwright “HCW@Home” Series
GlobeNewswire Inc.
Jun 11, 2025 12:00 PM GMT
HIGH POINT, N.C., June 11, 2025 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on the development of cadisegliatin, a potential first-in-class oral adjunctive therapy to insulin being in
vTv Therapeutics Appoints Michael Tung, M.D., MBA, to Chief Financial Officer as Company Reinitiates Phase 3 Trial of Oral T1D Adjunctive Therapy to Insulin
GlobeNewswire Inc.
May 19, 2025 1:00 PM GMT
HIGH POINT, N.C., May 19, 2025 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company, today announced the appointment of Michael Tung, M.D., MBA as Executive Vice President and Chief Financial Officer, eff
vTv Therapeutics Announces Reinitiation of Screening in CATT1 Phase 3 Trial Evaluating Potential First-in-Class Liver-Selective Glucokinase Activator Cadisegliatin for Type 1 Diabetes
GlobeNewswire Inc.
May 15, 2025 4:00 PM GMT
Topline CATT1 Phase 3 data is expected in 2H 2026 Protocol amendment shortens trial duration from 12 to 6 months, expediting time to topline data HIGH POINT, N.C., May 15, 2025 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage